SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high community anticipation for upcoming ASCO GU data on its ANKTIVA immunotherapy. Many expect this data to solidify the drug's position as a standard-of-care backbone for various cancers, driving strong conviction and 'buy the dip' sentiment despite persistent short pressure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is intensely trending ahead of its upcoming earnings report, with widespread anticipation for another strong performance driven by insatiable demand for its AI chips and innovations. However, community discussion is sharply divided on whether robust results will overcome concerns about past 'sell the news' patterns and options volatility.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is trending after reporting strong quarterly earnings that surpassed expectations, showcasing robust growth in USDC adoption and transaction volume, which has ignited bullish sentiment and discussions around its pivotal role as foundational digital dollar infrastructure amid debates on its valuation and market sensitivity.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is drawing significant attention after its Friedreich's ataxia drug, nomlabofusp, received FDA Breakthrough Therapy Designation, fueling bullish price target increases and active community discussion on its potential as a blockbuster, even with ongoing debate about managing side effects.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is highly discussed after an announced $175 million private equity placement caused a share price drop. Many in the community are debating whether the market's reaction to the dilution is an overcorrection, particularly as the funds are earmarked for strategic growth in space infrastructure and lunar services, including potential NASA contracts like the Lunar Terrain Vehicle award.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following strong preliminary Q4 and full-year revenue results, a record total contract value driven by expanding pharma partnerships, and new collaborations in genomic testing. The community is bullish, citing a new $100 price target from Mizuho and institutional interest, though some debate lingers about future growth guidance and profitability.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending due to outstanding Q4 earnings and highly optimistic 2026 revenue guidance, driven by surging demand for its fuel cell technology from energy-intensive AI data centers. The community is actively discussing its massive product backlog and potential for new all-time highs, despite some caution around its current high valuation and options-driven volatility.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech Ltd. is trending after a dramatic share price fall, driven by a forecast of substantial revenue decline in the upcoming quarter due to an advertising algorithm issue, as the community intensely debates if the sell-off is an overreaction or signals deeper concerns about the company's operational integrity.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending due to strong financial results and an upbeat multi-year outlook, particularly highlighting its expanding AI-powered public safety ecosystem. The community is actively discussing a significant short squeeze, seeing the company's hardware-software integration and market dominance as a key long-term growth story.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following strong Q4 earnings that surpassed analyst expectations, fueled by double-digit revenue growth and upbeat FY26 guidance for restaurant expansion and same-store sales. The market is buzzing with a perceived short squeeze, as bulls celebrate the upward momentum and increased price targets, while some express skepticism over the stock's high valuation despite its growth in the fast-casual dining sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...

Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...

D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00

D. Boral Capital cut their price target on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Friday...

<ul class="summary-bullets"><li>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs.</li><li>The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.</li><li>Immunic looks to prioritize its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026.</li></ul>Immunic Inc. (IMUX) announced on Friday that it has secured a private placement that could generate up to $400 million in gross proceeds, providing funding to advance its multiple sclerosis programs and support future product launches.The financing, led by existing investor BVF Partners and including several institutional backers, includes $200 million in upfront proceeds and the potential for an additional $200 million if warrants are exercised.&nbsp;The transaction is expected to close around February 17, pending customary conditions.<h2 class="st-heading-2">Financing To Advance Clinical Studies</h2>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs. Together with its existing cash and investments, the funds are expected to cover operating and capital costs through the end of 2027.The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/IMUX">Immunic stock</a> traded over 33% higher in Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h2 class="st-heading-2">Multiple Sclerosis Programs Take Priority&nbsp;</h2>Immunic plans complete its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026. The company aims to file a New Drug Application in mid-2027 and, if approved, launch in 2028. It also intends to initiate a Phase 3 program in primary progressive multiple sclerosis later this year, a trial projected to run up to four years.<blockquote>“The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS, as well as initiation of a phase 3 clinical program in PPMS.”-Daniel Vitt, CEO, Immunic</blockquote>Vitt will begin a search for a CEO to lead the next phase of growth. Vitt plans to transition into a senior strategic role while remaining on the board.IMUX stock has declined by 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aap-stock-surges-pre-market-what-s-fueling-the-rally/cZR5s0pR4sw">AAP Stock Surges 9% Pre-Market – What’s Fueling the Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IMUX Stock Surge 33% Pre-Market Today? 

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.  

Equity

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company Immunic Announces Oversubscribed Private Placement of up to USD...

HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)

HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Immunic in a research report on Monday...

Brookline Cap M Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Brookline Cap M issued their FY2025 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M...

Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M

Brookline Cap M raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$0.9001
Prev Close	$0.8983
Open	$0.881
Dividend Yield	0.00%
50-Day Moving Average	$0.6738
Beta	1.49
Avg. Volume	1.59M
PE Ratio	-1.04

52-Week High	$1.35
52-Week Low	$0.5062
Market Capitalization	$108.05M
EPS (Annual)	-$1.00
Price to Book	8.44
Revenue Per Employee	$0.00

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMUX News

IMUXImmunic Inc